Johnson County Clin-Trials — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,299,928	48
2024	Research	$11,113,941	256
2023	Research	$15,017,437	6,453
2022	Research	$13,792,144	4,465
2021	Research	$5,151,885	113
2020	Research	$575,547	10
2019	Research	$328,556	6

Breakdown

Who paid Research payments · program years 2019–2025

Moderna TX, Inc. $45,702,626 11,320 payments
Emergent BioSolutions Inc. $1,457,113 28 payments
Bavarian Nordic A/S $105,164 2 payments
Incyte Corporation $14,534 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $8,954,891 318 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $5,521,351 77 payments
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $3,700,472 85 payments
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults $3,055,178 1,670 payments
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age $2,617,679 931 payments
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $1,917,385 393 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,812,268 1,147 payments
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi $1,805,824 24 payments
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults 50 Years of Age $1,566,505 702 payments
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine,mRNA-1195, in Healthy Adults 18 to 55 Years of Age $1,305,600 1,111 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.